{"id":"amlodipine-standard-antihypertensive-therapy","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Peripheral edema"},{"rate":"7-16%","effect":"Headache"},{"rate":"4-6%","effect":"Flushing"},{"rate":"4-5%","effect":"Fatigue"},{"rate":"1-3%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle cells and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. When combined with standard antihypertensive agents, it provides additive blood pressure reduction through complementary mechanisms. This combination approach is used to achieve target blood pressure control in patients with hypertension.","oneSentence":"Amlodipine blocks L-type calcium channels in vascular smooth muscle to reduce blood pressure, used here as part of combination antihypertensive therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:37.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (as part of combination antihypertensive therapy)"}]},"trialDetails":[{"nctId":"NCT07099677","phase":"NA","title":"Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2025-08-01","conditions":"Hypertension, Fall Risk, Postural Balance","enrollment":186},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":"Hypertension","enrollment":35},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT03354143","phase":"PHASE2","title":"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-04-10","conditions":"Hypertension","enrollment":85},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT03264352","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"XueQing Yu","startDate":"2018-02-01","conditions":"Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure","enrollment":11414},{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT04692467","phase":"PHASE2","title":"Treatment of Early Hypertension Among Persons Living With HIV in Haiti","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-02-26","conditions":"HIV/AIDS, Pre Hypertension","enrollment":250},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT04978649","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy","status":"WITHDRAWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-01","conditions":"Diabetes Mellitus, Type 2, Blood Pressure","enrollment":""},{"nctId":"NCT02913664","phase":"PHASE2, PHASE3","title":"Risk Reduction for Alzheimer's Disease","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-02-02","conditions":"Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline","enrollment":513},{"nctId":"NCT05169021","phase":"PHASE4","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-12-31","conditions":"Cerebral Small Vessel Diseases, Stroke","enrollment":15000},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT03660397","phase":"PHASE3","title":"Adrenal Artery Ablation for Uncontrolled Hypertension","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2018-08-01","conditions":"Uncontrolled Hypertension","enrollment":40},{"nctId":"NCT02377661","phase":"PHASE4","title":"Lowering Blood Pressure in Primary Care in Vienna","status":"COMPLETED","sponsor":"Wilhelminenspital Vienna","startDate":"2015-03","conditions":"Hypertension","enrollment":229},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02817503","phase":"PHASE4","title":"Feasibility Study of the Intensive Systolic Blood Pressure Control","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2015-12","conditions":"Hypertension, Hyperhomocysteinemia","enrollment":100},{"nctId":"NCT01658657","phase":"NA","title":"A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-10","conditions":"Hypertension, Plasma Renin Activity","enrollment":17},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00834600","phase":"NA","title":"Renin Profiling in Selection of Initial Antihypertensive Drug","status":"COMPLETED","sponsor":"The Louis & Rachel Rudin Foundation","startDate":"2005-12","conditions":"Hypertension","enrollment":185}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8062,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard antihypertensive therapy"],"phase":"marketed","status":"active","brandName":"Amlodipine+standard antihypertensive therapy","genericName":"Amlodipine+standard antihypertensive therapy","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine blocks L-type calcium channels in vascular smooth muscle to reduce blood pressure, used here as part of combination antihypertensive therapy. Used for Hypertension (as part of combination antihypertensive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}